Shots:

• The P-III (ECHELON-1) clinical trial evaluating the safety and efficacy of Adcetris + AVD vs ABVD in 1334 adult patients with stage III or IV cHL
• The results showed an improvement in OS, following treatment with Adcetris + CT. At a median follow of ~ 6yrs., patients treated with the combination showed a 41% reduction in the risk of death & the safety profile was consistent with previous studies and no new safety signals were identified
• Adcetris has been approved for multiple types of r/r HL including prior untreated Stage III/IV cHL and PTCL & has received marketing authorization in 75+ countries and is being studied globally in 70+ clinical trials across multiple settings in lymphoma and other diseases

Ref: Businesswire | Image: Fierce Pharma